Literature DB >> 7429029

Glucose intolerance due to insulin resistance in patients with spinal cord injuries.

W C Duckworth, S S Solomon, P Jallepalli, C Heckemeyer, J Finnern, A Powers.   

Abstract

Glucose intolerance occurs frequently in patients with spinal cord injury (SCI). To characterize this better, 45 patients with spinal cord injuries received oral glucose tolerance tests (OGTT). The subjects with glucose intolerance had significantly higher insulin levels than either the glucose-tolerant or normal control subjects. Since hyperinsulinism in the presence of glucose intolerance suggests insulin resistance, the peripheral insulin activity (A) was calculated from the OGTT data. The glucose-intolerant SCI patients had significantly lower A values than the other groups. The most resistant SCI subjects (A < 0.3) also had resistance to exogenous insulin. In 18 subjects receiving insulin tolerance tests, the A value calculated from the OGTT was 100% accurate in predicting the presence of sensitivity or resistance to exogenous insulin. In spite of the presence of insulin resistance, however, 125I-insulin binding to SCI patients' circulating monocytes was not significantly different from that in control subjects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7429029     DOI: 10.2337/diab.29.11.906

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  54 in total

Review 1.  Effects of Use and Disuse on Non-paralyzed and Paralyzed Skeletal Muscles.

Authors:  David R Dolbow; Ashraf S Gorgey
Journal:  Aging Dis       Date:  2016-01-02       Impact factor: 6.745

2.  Effect of denervation on the expression of two glucose transporter isoforms in rat hindlimb muscle.

Authors:  N E Block; D R Menick; K A Robinson; M G Buse
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

3.  Dietary intake relative to cardiovascular disease risk factors in individuals with chronic spinal cord injury: a pilot study.

Authors:  Jesse Lieberman; David Goff; Flora Hammond; Pamela Schreiner; H James Norton; Michael Dulin; Xia Zhou; Lyn Steffen
Journal:  Top Spinal Cord Inj Rehabil       Date:  2014

Review 4.  Autonomic dysreflexia after spinal cord injury: Systemic pathophysiology and methods of management.

Authors:  Khalid C Eldahan; Alexander G Rabchevsky
Journal:  Auton Neurosci       Date:  2017-05-08       Impact factor: 3.145

Review 5.  Evidence-based and heuristic approaches for customization of care in cardiometabolic syndrome after spinal cord injury.

Authors:  Mark S Nash; Rachel E Cowan; Jochen Kressler
Journal:  J Spinal Cord Med       Date:  2012-09       Impact factor: 1.985

6.  Skeletal muscle mitochondrial mass is linked to lipid and metabolic profile in individuals with spinal cord injury.

Authors:  Laura C O'Brien; Qun Chen; Jeannie Savas; Edward J Lesnefsky; Ashraf S Gorgey
Journal:  Eur J Appl Physiol       Date:  2017-09-01       Impact factor: 3.078

7.  Glucocorticoid-induced insulin resistance: the importance of postbinding events in the regulation of insulin binding, action, and degradation in freshly isolated and primary cultures of rat hepatocytes.

Authors:  J F Caro; J M Amatruda
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

8.  31st g. Heiner sell lectureship: secondary medical consequences of spinal cord injury.

Authors:  William A Bauman; Mark A Korsten; Miroslav Radulovic; Gregory J Schilero; Jill M Wecht; Ann M Spungen
Journal:  Top Spinal Cord Inj Rehabil       Date:  2012

9.  Evidence for an exaggerated postprandial lipemia in chronic paraplegia.

Authors:  Mark S Nash; Joris DeGroot; Alberto Martinez-Arizala; Armando J Mendez
Journal:  J Spinal Cord Med       Date:  2005       Impact factor: 1.985

10.  Prediction of thigh skeletal muscle mass using dual energy x-ray absorptiometry compared to magnetic resonance imaging after spinal cord injury.

Authors:  Robert M Lester; Mina P Ghatas; Rehan M Khan; Ashraf S Gorgey
Journal:  J Spinal Cord Med       Date:  2019-02-01       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.